Some Breast Implant Cases Are Associated With Skin Cancer, FDA Receives Reports

Some Breast Implant Cases Are Associated With Skin Cancer, FDA Receives Reports
  • In a safety notice, the FDA has received several reports of certain cancers in the scar tissue around breast implants.
  • The FDA learned about these reports through continual postmarket reviews of breast implants and ongoing collaboration with external stakeholders. 
  • As of Sept. 1, 2022, the FDA had received ten reports about squamous cell carcinoma, a type of skin cancer, and 12 reports about various lymphomas related to breast implants.
  • Right now, we do not have enough information to say whether breast implants cause these cancers or if some implants pose a higher risk than others, the agency said in a separate report.
  • Earlier, the agency added new restrictions and warning labels for breast implants following reports of women who developed breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a cancer of the immune system.
  • The FDA said the new lymphoma cases were distinct from BIA-ALCL reported earlier.
  • It said the occurrence of cancers in scar tissues around an implant might be rare, and the incidence rate and risk factors are currently unknown.
  • Companies have their implants approved by the FDAAllergan owned by Abbvie Inc ABBVMentor, a Johnson & Johnson JNJ company, Sientra Inc SIEN, and Privately held Ideal Implant Incorporated.

Posted In: BriefsBiotechNewsPenny StocksHealth CareFDATop StoriesGeneral